Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026032957?dgcid=rss_sd_all
Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026032957?dgcid=rss_sd_all
“Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article41048,
title = {Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026032957?dgcid=rss_sd_all}
}